세계의 감염성 질환 분자진단 시장 : 시장 규모 분석(제품별, 기술별, 용도별, 최종 용도별, 지역별)과 예측(2022-2032년)

The global infectious disease molecular diagnostics market, valued at USD 52.0 billion in 2023, is anticipated to grow significantly at a compound annual growth rate (CAGR) of 3.9% during the forecast period of 2024 to 2032. The rising incidence of infectious diseases, driven by the persistent global burden of conditions like HIV/AIDS, tuberculosis, hepatitis, and respiratory infections, is a major factor propelling the market. This surge underscores the critical demand for precise, rapid diagnostic technologies capable of delivering actionable results.

Advanced molecular diagnostics, leveraging groundbreaking innovations in Polymerase Chain Reaction (PCR), nucleic acid amplification, and next-generation sequencing (NGS), have transformed diagnostic paradigms by enhancing detection accuracy and accelerating response times. These advances enable healthcare professionals to identify pathogens swiftly, improving patient outcomes and facilitating effective public health responses. Regulatory support and research funding have further catalyzed technological development, ensuring the industry continues to evolve and meet emerging diagnostic challenges.

Aging populations globally have amplified the demand for diagnostics, as older adults face heightened susceptibility to infections and related complications. Additionally, government-led initiatives promoting early detection and treatment have driven substantial investments in healthcare infrastructure, especially in emerging markets. Regions such as Asia Pacific and Latin America are experiencing significant growth due to enhanced access to diagnostic tools, bolstered by improved healthcare infrastructure and increased awareness.

Major market players are actively expanding their portfolios through mergers, acquisitions, and innovations in diagnostic reagents, services, and instrumentation. Reagents, in particular, dominated the market in 2023, holding a commanding 57.1% share. Their indispensability in diagnostic workflows, from PCR to PoC testing, has solidified their market leadership. Meanwhile, diagnostic services, driven by innovations like digital PCR and automated platforms, are projected to exhibit the fastest growth, offering comprehensive solutions for disease management.

Regionally, North America held the largest market share in 2023, fueled by high disease prevalence and robust healthcare systems. However, the Asia Pacific region is anticipated to lead the growth trajectory, with a projected CAGR of 6.9%, driven by its high infectious disease burden and increasing healthcare investments.

Major market players included in this report are:

• 1. Abbott
• 2. Danaher Corporation
• 3. Bio-Rad Laboratories, Inc.
• 4. bioMerieux SA
• 5. F. Hoffmann-La Roche Ltd
• 6. Agilent Technologies, Inc.
• 7. Becton, Dickinson and Company
• 8. Hologic, Inc. (Gen-Probe)
• 9. Illumina, Inc.
• 10. Grifols S.A.
• 11. Qiagen
• 12. Siemens Healthineers AG
• 13. Sysmex Corporation
• 14. Thermo Fisher Scientific, Inc.
• 15. Luminex Corporation

The detailed segments and sub-segment of the market are explained below:

By Product:

• Instruments
• Reagents
• Services

By Technology:

• Polymerase Chain Reaction (PCR)
• Multiplex PCR
• In Situ Hybridization (ISH)
• Isothermal Nucleic Acid Amplification Technology (INAAT)
• Chips and Microarrays
• Mass Spectrometry
• Transcription Mediated Amplification
• Others

By Application:

• Respiratory Diseases
• Tuberculosis
• HPV
• Sepsis
• Others

By End Use:

• Hospitals
• Clinics
• Diagnostic Laboratories
• Research Institutes

By Region:

• North America
• U.S.
• Canada
• Europe
• UK
• Germany
• France
• Italy
• Spain
• Rest of Europe
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• Rest of Asia Pacific
• Latin America
• Brazil
• Mexico
• Rest of Latin America
• Middle East & Africa
• Saudi Arabia
• South Africa
• Rest of MEA

Years considered for the study are as follows:

• Historical year - 2022
• Base year - 2023
• Forecast period - 2024 to 2032

Key Takeaways:

• Market Estimates & Forecast for 10 years from 2022 to 2032.
• Annualized revenues and regional-level analysis for each market segment.
• Competitive landscape with information on major players in the market.
• Analysis of key business strategies and recommendations on future market approaches.

Table of Contents

Chapter 1. Global Infectious Disease Molecular Diagnostics Market Executive Summary

• 1.1. Global Infectious Disease Molecular Diagnostics Market Size & Forecast (2022-2032)
• 1.2. Regional Summary
• 1.3. Segmental Summary
  • 1.3.1. By Product
  • 1.3.2. By Technology
  • 1.3.3. By Application
  • 1.3.4. By End Use
• 1.4. Key Trends
• 1.5. Recession Impact
• 1.6. Analyst Recommendation & Conclusion

Chapter 2. Global Infectious Disease Molecular Diagnostics Market Definition and Research Assumptions

• 2.1. Research Objective
• 2.2. Market Definition
• 2.3. Research Assumptions
  • 2.3.1. Inclusion & Exclusion
  • 2.3.2. Limitations
  • 2.3.3. Supply Side Analysis
    • 2.3.3.1. Availability
    • 2.3.3.2. Infrastructure
    • 2.3.3.3. Regulatory Environment
    • 2.3.3.4. Market Competition
    • 2.3.3.5. Economic Viability (Consumer's Perspective)
  • 2.3.4. Demand Side Analysis
    • 2.3.4.1. Regulatory Frameworks
    • 2.3.4.2. Technological Advancements
    • 2.3.4.3. Environmental Considerations
    • 2.3.4.4. Consumer Awareness & Acceptance
• 2.4. Estimation Methodology
• 2.5. Years Considered for the Study
• 2.6. Currency Conversion Rates

Chapter 3. Global Infectious Disease Molecular Diagnostics Market Dynamics

• 3.1. Market Drivers
  • 3.1.1. Rising Prevalence of Infectious Diseases
  • 3.1.2. Technological Advancements in Diagnostics
  • 3.1.3. Government Initiatives & Funding
• 3.2. Market Challenges
  • 3.2.1. High Costs of Advanced Diagnostics
  • 3.2.2. Regulatory Hurdles
• 3.3. Market Opportunities
  • 3.3.1. Emerging Markets in Asia Pacific and Latin America
  • 3.3.2. Integration of AI in Diagnostics

Chapter 4. Global Infectious Disease Molecular Diagnostics Market Industry Analysis

• 4.1. Porter's 5 Force Model
  • 4.1.1. Bargaining Power of Suppliers
  • 4.1.2. Bargaining Power of Buyers
  • 4.1.3. Threat of New Entrants
  • 4.1.4. Threat of Substitutes
  • 4.1.5. Competitive Rivalry
  • 4.1.6. Futuristic Approach to Porter's 5 Force Model
  • 4.1.7. Porter's 5 Force Impact Analysis
• 4.2. PESTEL Analysis
  • 4.2.1. Political
  • 4.2.2. Economical
  • 4.2.3. Social
  • 4.2.4. Technological
  • 4.2.5. Environmental
  • 4.2.6. Legal
• 4.3. Top Investment Opportunities
• 4.4. Top Winning Strategies
• 4.5. Disruptive Trends
• 4.6. Industry Expert Perspective
• 4.7. Analyst Recommendation & Conclusion

Chapter 5. Global Infectious Disease Molecular Diagnostics Market Size & Forecast by Product 2022-2032

• 5.1. Segment Dashboard
• 5.2. Global Infectious Disease Molecular Diagnostics Market: Product Revenue Trend Analysis, 2022 & 2032 (USD Million)
  • 5.2.1. Instruments
  • 5.2.2. Reagents
  • 5.2.3. Services

Chapter 6. Global Infectious Disease Molecular Diagnostics Market Size & Forecast by Technology 2022-2032

• 6.1. Segment Dashboard
• 6.2. Global Infectious Disease Molecular Diagnostics Market: Technology Revenue Trend Analysis, 2022 & 2032 (USD Million)
  • 6.2.1. Polymerase Chain Reaction (PCR)
  • 6.2.2. In Situ Hybridization (ISH)
  • 6.2.3. Isothermal Nucleic Acid Amplification Technology (INAAT)
  • 6.2.4. Chips and Microarrays
  • 6.2.5. Mass Spectrometry
  • 6.2.6. Transcription Mediated Amplification
  • 6.2.7. Others

Chapter 7. Global Infectious Disease Molecular Diagnostics Market Size & Forecast by Application 2022-2032

• 7.1. Segment Dashboard
• 7.2. Global Infectious Disease Molecular Diagnostics Market: Application Revenue Trend Analysis, 2022 & 2032 (USD Million)
  • 7.2.1. Respiratory Diseases
  • 7.2.2. Tuberculosis
  • 7.2.3. HPV
  • 7.2.4. Sepsis
  • 7.2.5. Others

Chapter 8. Global Infectious Disease Molecular Diagnostics Market Size & Forecast by End Use 2022-2032

• 8.1. Segment Dashboard
• 8.2. Global Infectious Disease Molecular Diagnostics Market: End Use Revenue Trend Analysis, 2022 & 2032 (USD Million)
  • 8.2.1. Hospitals
  • 8.2.2. Clinics
  • 8.2.3. Diagnostic Laboratories
  • 8.2.4. Research Institutes

Chapter 9. Global Infectious Disease Molecular Diagnostics Market Size & Forecast by Region 2022-2032

• 9.1. North America
  • 9.1.1. U.S.
  • 9.1.2. Canada
• 9.2. Europe
  • 9.2.1. UK
  • 9.2.2. Germany
  • 9.2.3. France
  • 9.2.4. Italy
  • 9.2.5. Spain
  • 9.2.6. Rest of Europe
• 9.3. Asia-Pacific
  • 9.3.1. China
  • 9.3.2. Japan
  • 9.3.3. India
  • 9.3.4. Australia
  • 9.3.5. South Korea
  • 9.3.6. Rest of Asia Pacific
• 9.4. Latin America
  • 9.4.1. Brazil
  • 9.4.2. Mexico
  • 9.4.3. Rest of Latin America
• 9.5. Middle East & Africa (MEA)
  • 9.5.1. Saudi Arabia
  • 9.5.2. South Africa
  • 9.5.3. Rest of MEA

Chapter 10. Competitive Intelligence

• 10.1. Key Company SWOT Analysis
  • 10.1.1. Danaher Corporation
  • 10.1.2. Abbott
  • 10.1.3. F. Hoffmann-La Roche Ltd
• 10.2. Top Market Strategies
• 10.3. Company Profiles
  • 10.3.1. Danaher Corporation
  • 10.3.2. Abbott
  • 10.3.3. F. Hoffmann-La Roche Ltd
  • 10.3.4. Bio-Rad Laboratories, Inc.
  • 10.3.5. Siemens Healthineers AG
  • 10.3.6. Illumina, Inc.
  • 10.3.7. Qiagen
  • 10.3.8. Sysmex Corporation
  • 10.3.9. Becton, Dickinson and Company
  • 10.3.10. bioMerieux SA

Chapter 11. Research Process

• 11.1. Research Process
  • 11.1.1. Data Mining
  • 11.1.2. Analysis
  • 11.1.3. Market Estimation
  • 11.1.4. Validation
  • 11.1.5. Publishing
• 11.2. Research Attributes